Vito Quaranta
-
Research Snapshot: Development of a new framework and tool for multi-drug synergy and combination
MuSyC is a technique to help researchers devise new combinations of drugs. An open-source analysis tool, it holds the promise speed such discoveries around the world. Read MoreAug 24, 2021
-
Vanderbilt CTTC commercialized 25 COVID-19-related discoveries, facilitated nine startups during record-setting year
The Center for Technology Transfer and Commercialization continued to play a pivotal role in translating the research findings of Vanderbilt faculty into products and companies in 2020 that have the potential to transform many aspects of life, from disease prevention to quality of life-enhancing products. Read MoreMay 12, 2021
-
Interdisciplinary melanoma research brings understanding of cellular resistance to cancer treatment, opening doors to new cures
Drug-tolerant persister cells–those that survive cancer treatment–found to rely on similar survival mechanisms across cancers, in a groundbreaking study led by Vanderbilt researchers. Read MoreOct 21, 2020
-
New algorithm calculates drug synergy; initial tests involve melanoma, lung cancer
Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. Oncologists haven’t had the right tools to predict drug interactions, other than in costly clinical trials. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team… Read MoreFeb 20, 2019
-
$8.1 million grant funds new center to research highly aggressive form of lung cancer
A five-year National Cancer Institute grant will fund an interdisciplinary research center for the study of small cell lung cancer, a highly aggressive, incurable form of the disease. Read MoreJun 8, 2018
-
“Idling” cancer cells may return
Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment. Read MoreApr 11, 2018
-
Melanoma study finds new way to enhance targeted therapies
With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy. Read MoreMar 9, 2017
-
Current cancer drug discovery method flawed: VUMC study
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods. Read MoreMay 5, 2016
-
Ten Vanderbilt faculty members elected AAAS fellows
Ten members of Vanderbilt University’s faculty have been elected fellows of the American Association for the Advancement of Science. Read MoreNov 23, 2015
-
Method may refine personalized trials for cancer therapy
A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy, and may offer a way to further refine personalized cancer treatments. Read MoreAug 16, 2012
-
Protein ‘scissors’ cut path for cancer
The protein matriptase "cuts" a key component of the prostate tissue barrier and may be involved in prostrate cancer progression, new research finds. Read MoreFeb 22, 2011